Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials

[1]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[2]  D. Angiolillo,et al.  Novel antiplatelet agents in acute coronary syndrome , 2015, Nature Reviews Cardiology.

[3]  R. Schulz,et al.  Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. , 2014, Journal of the American College of Cardiology.

[4]  Deepak L. Bhatt,et al.  Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data , 2013, The Lancet.

[5]  M. Krucoff,et al.  Electrocardiographic Safety of Cangrelor, a New Intravenous Antiplatelet Agent: A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Thorough QT Study , 2013, Journal of cardiovascular pharmacology.

[6]  D. Angiolillo,et al.  Cangrelor: a review on pharmacology and clinical trial development , 2013, Expert review of cardiovascular therapy.

[7]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[8]  David J Cohen,et al.  Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. , 2013, JAMA.

[9]  Deepak L. Bhatt,et al.  A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial , 2012, Circulation. Cardiovascular interventions.

[10]  D. Angiolillo,et al.  Antithrombotic Therapy in Patients With Chronic Kidney Disease , 2012, Circulation.

[11]  Deepak L. Bhatt,et al.  Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials , 2012, Journal of Thrombosis and Thrombolysis.

[12]  M. Sabatine,et al.  Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. , 2012, Journal of the American College of Cardiology.

[13]  Sunil V. Rao,et al.  Bleeding and acute coronary syndromes: defining, predicting, and managing risk and outcomes. , 2011, Current Drug Targets.

[14]  Davide Capodanno,et al.  Antithrombotic therapy in the elderly. , 2010, Journal of the American College of Cardiology.

[15]  D. Angiolillo,et al.  Impact of race and gender on antithrombotic therapy , 2010, Thrombosis and Haemostasis.

[16]  Sunil V. Rao,et al.  The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. , 2010, Journal of the American College of Cardiology.

[17]  M. Cavender,et al.  Bleeding associated with current therapies for acute coronary syndrome: What are the mechanisms? , 2010, Journal of Thrombosis and Thrombolysis.

[18]  Gregg W Stone,et al.  Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.

[19]  Deepak L. Bhatt,et al.  Intravenous platelet blockade with cangrelor during PCI. , 2009, The New England journal of medicine.

[20]  J. Ware,et al.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.

[21]  A. Kastrati,et al.  Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.

[22]  S. Yusuf,et al.  Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.

[23]  K. Alexander,et al.  Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. , 2005, JAMA.

[24]  E. Antman,et al.  Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (E , 2005, American heart journal.

[25]  H. White,et al.  Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. , 2004, American heart journal.

[26]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.